Search Technologies

The Frederick National Laboratory for Cancer Research seeks parties interested in collaborative research to co-develop software for the automatic 3-D visualization of biological image volumes.

Researchers at the National Cancer Institute (NCI) developed novel groups of cyanine (Cy) based antibody-drug conjugate (ADC) chemical linkers that undergo photolytic cleavage upon irradiation with near-IR light. By using the fluorescent properties of the Cy linker to monitor localization of the ADC, and subsequent near-IR irradiation of cancerous tissue, drug release could be confined to the tumor microenvironment.

The National Cancer Institute seeks parties interested to license a method to generate RNA molecules suitable for nanoparticle and biomedical applications.

The National Cancer Institute, Laboratory of Molecular Biology seeks parties to co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers.

Researchers at the National Cancer Institute (NCI) developed a multiplex assay to determine the efficacy of apoptosis-related drugs targeting the Bcl2 family of proteins or aid in the selection of cancer patients likely to respond. The NCI seeks partners for co-development or licensees for commercialization of novel immunoassays for determining or predicting patient response to cancer therapy.

Researchers at the National Institutes for Health Clinical Center (NIHCC) have developed computer-aided diagnostics (CAD) that may further improve the already superior capabilities of multiparametric magnetic resonance imaging (MRI) for detection and imaging of prostate cancer. This system produces an accurate probability map of potential cancerous lesions in multiparametric MRI images that is superior to other systems and may have multiple product applications.

Researchers at the National Cancer Institute (NCI) identified a biomarker signature of viral infection that correlates with hepatocellular carcinoma (HCC) incidence in at-risk individuals. It has been validated in a longitudinal cohort to detect HCC with high sensitivity and specificity up to 7 years prior to clinical diagnosis. This viral exposure signature can be easily implemented into diagnostic assays for screening of HCC and is available for licensing and/or co-development opportunities.

Researchers at the National Cancer Institute (NCI) have developed a gene-expression profiling-based molecular diagnostic assay to diagnose and classify primary mediastinal large B cell lymphoma (PMBCL) from diffuse large B cell lymphoma (DLBCL). The diagnosis can be done using routinely available formalin-fixed, paraffin-embedded (FFPE) biopsies. The NCI seeks licensees and/or co-development partners to commercialize this technology.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks research co-development partners and/or licensees to further develop and commercialize its methods of noninvasively and directly determining the absolute homeostatic state, metabolic activity, function, and viability of isolated cells, or tissues (ex vivo or in vivo), such as the Central Nervous System (CNS). The method uses Nuclear Magnetic Resonance or Magnetic Resonance Imaging measurements of the rate at which endogenous water exchanges across cell membranes.